Article Information
History
- June 6, 2021.
Article Versions
- Version 1 (January 26, 2021 - 11:42).
- Version 2 (February 10, 2021 - 09:07).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Katy Gaythorpe1,*,
- Kaja Abbas2,*,
- John Huber3,*,
- Andromachi Karachaliou4,*,
- Niket Thakkar5,*,
- Kim Woodruff1,
- Xiang Li1,
- Susy Echeverria-Londono1,
- VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease,
- Matthew Ferrari6,^,
- Michael L. Jackson7,^,
- Kevin McCarthy5,^,
- Alex Perkins3,^,
- Caroline Trotter4,^ and
- Mark Jit2,8,#^
- 1MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom
- 2Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
- 3Department of Biological Sciences, University of Notre Dame, South Bend, Indiana, United States of America
- 4Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
- 5Institute for Disease Modelling, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America
- 6Pennsylvania State University, University Park, Pennsylvania, United States of America
- 7Kaiser Permanante Washington, Seattle, Washington, United States of America
- 8School of Public Health, University of Hong Kong, Hong Kong SAR, China
- ↵#Corresponding author: Mark Jit, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. Telephone: +44 (0)207 927 2852. Email: mark.jit{at}lshtm.ac.uk.